ATE223200T1 - Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel - Google Patents

Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel

Info

Publication number
ATE223200T1
ATE223200T1 AT97911223T AT97911223T ATE223200T1 AT E223200 T1 ATE223200 T1 AT E223200T1 AT 97911223 T AT97911223 T AT 97911223T AT 97911223 T AT97911223 T AT 97911223T AT E223200 T1 ATE223200 T1 AT E223200T1
Authority
AT
Austria
Prior art keywords
gum
xanthang
eye medicinal
inhibitor
medicinal containing
Prior art date
Application number
AT97911223T
Other languages
English (en)
Inventor
Gilles Chastaing
Bernard Plazonnet
Annouk Rozier
Original Assignee
Merck Sharp & Dohme Chibret Sn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Chibret Sn filed Critical Merck Sharp & Dohme Chibret Sn
Application granted granted Critical
Publication of ATE223200T1 publication Critical patent/ATE223200T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT97911223T 1996-10-17 1997-10-09 Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel ATE223200T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9612658A FR2754712B1 (fr) 1996-10-17 1996-10-17 Compositions ophtalmiques
PCT/EP1997/005678 WO1998017249A1 (en) 1996-10-17 1997-10-09 Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum

Publications (1)

Publication Number Publication Date
ATE223200T1 true ATE223200T1 (de) 2002-09-15

Family

ID=9496748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97911223T ATE223200T1 (de) 1996-10-17 1997-10-09 Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel

Country Status (13)

Country Link
US (1) US6264935B1 (de)
EP (1) EP0932389B1 (de)
JP (1) JP2001508035A (de)
AT (1) ATE223200T1 (de)
AU (1) AU715223B2 (de)
CA (1) CA2269552A1 (de)
DE (1) DE69715228T2 (de)
ES (1) ES2183148T3 (de)
FR (1) FR2754712B1 (de)
HR (1) HRP970552A2 (de)
PE (1) PE106998A1 (de)
WO (1) WO1998017249A1 (de)
ZA (1) ZA979219B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
JP2003513046A (ja) 1999-11-01 2003-04-08 アルコン，インコーポレイテッド フルオロキノロン抗生薬およびキサンタンガムを含有する薬学的組成物
AU2001270593A1 (en) 2000-07-28 2002-02-13 Alcon Universal Ltd. Pharmaceutical compositions containing tobramycin and xanthan gum
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
PL373433A1 (en) * 2002-08-30 2005-08-22 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
PT1572217E (pt) * 2002-12-12 2008-11-28 Nycomed Gmbh Medicamento combinado de r,r-formoterol e ciclesonida
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
WO2006035969A1 (ja) * 2004-09-28 2006-04-06 Senju Pharmaceutical Co., Ltd. キサンタンガムおよびアミノ酸を含有する眼科用組成物
ES2337501T3 (es) * 2005-07-11 2010-04-26 Senju Pharmaceutical Co., Ltd. Preparacion oftalmica que comprende goma de xantano y terpenoide.
BRPI0620080A2 (pt) * 2005-12-19 2011-11-01 Comentis Inc formulações tópicas de mecamilamina para adminstração ocular e usos das mesma
WO2007108541A1 (ja) 2006-03-23 2007-09-27 Senju Pharmaceutical Co., Ltd. キサンタンガムおよびブドウ糖を含有する眼科用組成物
MX2009001037A (es) 2006-07-31 2009-05-15 Senju Pharma Co Preparacion liquida acuosa que contiene compuesto de amida.
WO2010004594A1 (en) * 2008-07-08 2010-01-14 S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. Ophthalmic compositions for treating pathologies of the posterior segment of the eye
AU2014348620A1 (en) * 2013-11-15 2016-06-16 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
WO2016063184A1 (en) * 2014-10-20 2016-04-28 Sentiss Pharma Private Limited Ophthalmic solution
IT202000002296A1 (it) * 2020-02-06 2021-08-06 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136173A (en) 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4136178A (en) 1977-01-31 1979-01-23 American Home Products Corp. Locust bean gum therapeutic compositions
US4136177A (en) 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US5157044A (en) 1983-02-04 1992-10-20 University Of Iowa Research Foundation Analogs of carbonic anhydrase inhibitors and their use as topical IOP inhibitors
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4876271A (en) 1988-12-20 1989-10-24 Merck & Co., Inc. Substituted thieno[3,2-b]thiophene-2-sulfonamides as topically active carbonic anhydrase inhibitors
US4929549A (en) 1989-02-08 1990-05-29 Merck & Co., Inc. 5-carbamoylthieno[2,3-b]thiophene-2-sulfon-amides as topically active carbonic anhydrase inhibitors
US5120757A (en) 1989-07-31 1992-06-09 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents
FR2657018A1 (fr) 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
US5242937A (en) 1990-03-19 1993-09-07 Research Corporation Technologies, Inc. Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
US5055480A (en) 1990-03-19 1991-10-08 Research Corporation Technologies, Inc. Topically active ocular gem-diacylthiadiazole sulfonamide carbonic anhydrase inhibitors
US5059613A (en) 1990-03-19 1991-10-22 Research Corporation Technologies, Inc. Topically active ocular benzothiazole sulfonamide carbonic anhydrase inhibitors
IE911192A1 (en) 1990-04-12 1991-10-23 Merck & Co Inc Substituted aromatic sulfonamides as antiglaucoma agents
CA2040460C (en) 1990-05-01 1997-06-10 Tacey X. Viegas Drug delivery with thermoreversible gels
US5091409A (en) 1990-05-17 1992-02-25 Merck & Co., Inc. 4-alkylamino-6-(C3-5 -hydrocarbyl)thieno[2,3-B]thiopyran-2-sulfonamide-7,7-dioxides
US5093332A (en) 1990-10-01 1992-03-03 Merck & Co., Inc. Substituted thieno(2,3-b)(1,4)thiazine-6-sulfonamides as antiglaucoma agents
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
AU3722793A (en) 1992-09-17 1994-04-12 Alcon Laboratories, Inc. Topical carbonic anhydrase inhibitor composition
SE9301877D0 (sv) * 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
CA2337349A1 (en) * 1998-07-21 2000-02-03 Gerald S. Ponticello Ophthalmic compositions for treating ocular hypertension

Also Published As

Publication number Publication date
ZA979219B (en) 1998-07-17
PE106998A1 (es) 1999-01-23
EP0932389B1 (de) 2002-09-04
AU715223B2 (en) 2000-01-20
EP0932389A1 (de) 1999-08-04
DE69715228D1 (de) 2002-10-10
DE69715228T2 (de) 2003-06-05
FR2754712B1 (fr) 1999-09-03
AU4867397A (en) 1998-05-15
JP2001508035A (ja) 2001-06-19
ES2183148T3 (es) 2003-03-16
FR2754712A1 (fr) 1998-04-24
US6264935B1 (en) 2001-07-24
WO1998017249A1 (en) 1998-04-30
HRP970552A2 (en) 1998-08-31
CA2269552A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
DE69715228D1 (de) Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
EP1224935A3 (de) Prostaglandoin-Derivate zur Behandlung von Glaukom und ocularer Hypertension
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
ATE480240T1 (de) Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom
EP1110554A4 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
BR0012696A (pt) Composição oftálmica
ATE78031T1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
ATE215821T1 (de) Entzündungshemmende augentropfen
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
HUP9802553A2 (hu) Karbonanhidratáz inhibitorok alkalmazása a retina véráramának növelésére szolgáló gyógyszerkészítmények előállítására
WO1992000287A3 (en) Analogs of carbonic anhydrase inhibitors and their use as topical iop inhibitors
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
AU648659C (en) Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a beta-adrenergic antagonist
ATE289198T1 (de) Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
MX9405209A (es) Uso de las n-(piridinil)-1h-indol-1-aminas en la preparacion de unmedicamento para el tratamiento de desordenes obsesivo-compulsivos.
ATE215824T1 (de) Mittel zur verminderung des augeninnendrucks
ECSP972285A (es) Composiciones oftalmicas
DE69829227D1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
CA2423288A1 (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
WO2001082913A3 (en) Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
BG96092A (bg) Тиенотиопиранови сулфонамидни производни и приложението им в офталмологични препарати

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties